| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
Lactitol dihydrate does not have a classical drug target. As an osmotic laxative, its mechanism of action is based on its physical properties. It is poorly absorbed from the gastrointestinal tract and draws water into the bowel by osmosis, which increases stool volume and stimulates bowel movements. This osmotic effect is the basis of its therapeutic use in constipation.
|
|---|---|
| ln Vitro |
Lactitol dihydrate is not used in pharmacological activity assays. Its properties are assessed based on its chemical and physical characteristics, such as purity, solubility, and stability. Its sweetness and noncariogenic properties are evaluated in food science applications.
|
| ln Vivo |
Lactitol dihydrate is used in vivo as an osmotic laxative to treat chronic idiopathic constipation in adults. It was approved in 2020 for medical use as an oral solution to help produce bowel movements. Its effects are local in the gastrointestinal tract, drawing water into the bowel to promote defecation.
|
| Enzyme Assay |
Lactitol dihydrate does not have a typical enzyme/receptor binding assay. Its properties are evaluated based on its chemical and physical characteristics, such as purity, solubility, and stability. Its osmotic activity can be assessed in vitro by measuring its ability to draw water across a semi-permeable membrane.
|
| Cell Assay |
Lactitol dihydrate is not typically used in cell-based assays. Its applications are primarily in food science and as a pharmaceutical excipient. The compound's effects on cells are not a primary focus of study, as it is not intended for biological or therapeutic use beyond its laxative effect.
|
| Animal Protocol |
In vivo animal experiments for Lactitol dihydrate would involve administering the compound to animal models of constipation to assess its laxative efficacy. Its effects on stool volume, consistency, and frequency would be evaluated. However, specific in vivo data is limited.
|
| ADME/Pharmacokinetics |
Lactitol dihydrate has a molecular weight of 344.31 g/mol and a molecular formula of C12H28O13. It is a white, odorless powder with high water solubility. It is stable under a range of pH conditions and is resistant to enzymatic hydrolysis by most mammalian digestive enzymes.
|
| Toxicity/Toxicokinetics |
Lactitol dihydrate is generally recognized as safe (GRAS) for use as a food additive and as a pharmaceutical excipient. It is well-tolerated, although high doses may cause gastrointestinal side effects such as flatulence and diarrhea. Its safety has been established for use in food and pharmaceutical products.
|
| References | |
| Additional Infomation |
Lactitol dihydrate is a polymer.
Lactitol dihydrate is a sugar alcohol used as a noncariogenic sweetener and as an osmotic laxative. It is a crystalline disaccharide polyol derived from lactose. It was approved in 2020 for the treatment of chronic idiopathic constipation in adults. It is available from various chemical suppliers for research and industrial purposes. |
| Molecular Formula |
C11H26O13
|
|---|---|
| Molecular Weight |
366.3163
|
| Exact Mass |
380.153
|
| CAS # |
81025-03-8
|
| Related CAS # |
81025-03-8 (hydrate);585-86-4 (free);
|
| PubChem CID |
157354
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
343
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O.O.O
|
| InChi Key |
VAOUPFUEMFJHKI-MTURKXFLSA-N
|
| InChi Code |
InChI=1S/C12H24O11.2H2O/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12;;/h4-21H,1-3H2;2*1H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-;;/m0../s1
|
| Chemical Name |
(2S,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol;dihydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7299 mL | 13.6493 mL | 27.2985 mL | |
| 5 mM | 0.5460 mL | 2.7299 mL | 5.4597 mL | |
| 10 mM | 0.2730 mL | 1.3649 mL | 2.7299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
